PegIFN beta-1a for relapsing-remitting MS: 2 years are better than 1

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • 2 y of peginterferon (pegIFN) beta-1a was superior to 1 y in patients with relapsing-remitting multiple sclerosis (MS).

Why this matters

  • Long-term efficacy of peginterferon beta-1a is unknown.

Key results

  • Compared with the delayed treatment group, the peginterferon beta-1a every 2 wk group more often achieved no evidence of disease according to MRI criteria (41% vs 21%; OR, 2.56), clinical criteria (71% vs 57%; OR, 1.90), or both (37% vs 16%; OR, 3.09).
  • Changes in MRI measures suggested that peginterferon beta-1a treatment was associated with pseudoatrophy during the first 6 mo of treatment that began to resolve thereafter.

Study design

  • Randomized controlled trial of 1512 patients with relapsing-remitting MS.
  • For the first year, patients were randomly assi...